Evidence map›Paper›PMID 32843426›Full record

ArticleCold Spring Harbor molecular case studies2020

Dual inhibition of BRAF and mTOR in

Shiraj Sen, Ryuma Tanaka, Soumen Khatua, Wafik Zaky, Filip Janku, Marta Penas-Prado, Shiao-Pei Weathers, Amini Behrang, Jason Roszik, Vivek Subbiah

Open access · diamondAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Response and resistance to BRAFFrontiers in oncology · 2022
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Shiraj SenSarah Cannon Research Institute at HealthONE, Denver, Colorado 80218, USA.
Ryuma TanakaPediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Soumen KhatuaPediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Wafik ZakyPediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Filip JankuInvestigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Marta Penas-PradoNeuro-oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Shiao-Pei WeathersNeuro-oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Amini BehrangDiagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Jason RoszikDepartment of Melanoma Medical Oncology and Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Vivek SubbiahPediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.ORCID 0000-0002-6064-6837
The University of Texas MD Anderson Cancer Center · USSarah Cannon Research Institute · GB

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4M
Informatics to enable routine personalized cancer therapyU01CA180964 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI BERNSTAM, ELMER V., MERIC-BERNSTAM, FUNDA · 2013 to 2015
$964k
NCATS NIH HHS UL1 TR000371NCI NIH HHS P30 CA016672NCI NIH HHS U01 CA180964
6 · The paper itself

Abstract

Although BRAF inhibition has demonstrated activity in

Indexed as

AdolescentAdultBrain NeoplasmsChildDrug Resistance, NeoplasmEverolimusHumansMutationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafTOR Serine-Threonine KinasesVemurafenibYoung AdultBRAF protein, humanEverolimusMTOR protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafTOR Serine-Threonine KinasesVemurafenibneoplasm of the central nervous system

Identifiers

PMID32843426
PMCPMC7476413
OpenAlexW3080299398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.